Market News & Trends
Charleston Laboratories Announces Completion of Second Phase III Trial
Charleston Laboratories, Inc. recently announced completion of their second Phase III clinical study on CL-108, a novel bi-layered tablet containing 7.5 mg of hydrocodone and…
NanoViricides Reports Dramatic Effects of Topical Anti-Herpes Treatment Were Reproduced Once Again
NanoViricides, Inc. recently reported that the dramatic improvements in clinical symptoms associated with herpes simplex virus infection were reproduced in an animal model in a…
BioClin Therapeutics Initiates Phase II Clinical Trial for Urothelial Cell Carcinoma
BioClin Therapeutics, Inc. recently announced it has initiated a Phase II clinical study of B-701, an anti-FGFR3 antibody being investigated for the treatment of locally…
Pluristem in Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, recently announced it has conducted detailed discussions with the European Adaptive Pathways Discussion Group…
Corbion & MedinCell Form Strategic Joint Venture
The joint venture, CM Biomaterials, will sell the PEG / PLA co-polymers to MedinCell partners who license the MedinCell technology (BEPO). Manufacturing of the polymers…
HERMES PHARMA Brings Easy-to-Swallow Medicines to US Market
HERMES PHARMA, Europe's largest developer and manufacturer of user-friendly solid oral dosage forms, recently announced plans to ramp up its expansion into the US market.…
Proteon Therapeutics Initiates Second Phase III Clinical Study
Proteon Therapeutics Inc. recently announced that the first patient has been treated in a second Phase III clinical study of investigational vonapanitase (formerly PRT-201), the…
Theravance Biopharma Receives FDA Fast Track Designation
Theravance Biopharma, Inc. recently announced that the US Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for short-term use with enteral feeding…
RegeneRx Biopharmaceuticals Provides Update On Clinical Trials
RegeneRx Biopharmaceuticals, Inc. recently provided an update on the status and timing of the four ophthalmic clinical trials for dry eye syndrome and neurotrophic keratopathy…
Metrics Contract Services Invests in Leading Liquid Chromatography Technologies
Metrics has acquired two new Waters ACQUITY Ultra Performance Liquid Chromatography H-class (UPLC) systems. These additional UPLC systems will help the company’s chemists produce better…
Marina Biotech’s CEQ508 Granted FDA Fast Track Designation for RNAi Therapeutic
Marina Biotech, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CEQ508, an investigational RNAi therapeutic for…
Catalent's Proprietary Softgel Technology Used to Provide Daily Dosing of Modified-Release Semi-Solid Formulation
Catalent Pharma Solutions recently welcomed the announcement by OPKO Health that the US Food and Drug Administration has accepted for review OPKO’s New Drug Application…
Sigma-Aldrich's $17-Billion Buy-Out Seen as Boost for Lab Suppliers
By: Bill Berkrot The large premium Germany's Merck KGaA (MRCG.DE) agreed to pay in a $17-billion (10.37 billion pounds) acquisition of Sigma-Aldrich Corp (SIAL.O) shines…
CELLSEARCH System Recognized as Landmark Innovation in Cancer Research
Janssen Diagnostics recently announced that a clinical trial involving the company’s CELLSEARCH System has been recognized by the editors of Clinical Cancer Research1 as being…
Oncology Treatment Offers Significant Opportunities With Largest Pipeline in Pharmaceuticals
The oncology drug pipeline is far larger than any other therapy area across the pharmaceutical industry, with 6,484 products in active development across all indications,…
NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
LAGUNA HILLS, Calif., July 30, 2015 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from…
Unilife Introduces World's First Instant Patch Pump for Insulin
York, PA. – July 29, 2015. Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery…
Xcelience Makes Structured Cash Investment in Powdersize
TAMPA, FLORIDA (July 31, 2015) – Xcelience, a contract development and manufacturing organization (CDMO), recently announced that it has made a structured cash investment in…
CANbridge Acquires License for Apogenix’s Onco-Immunotherapy
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive license agreement with…
AnaptysBio Secures $40-Million Financing
AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, recently announced the completion of an oversubscribed $40MM Series…